Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure.
暂无分享,去创建一个
Kevin J. Anstrom | Daniel B. Mark | Tariq Ahmad | Christopher M. O'Connor | K. Anstrom | I. Piña | E. Leifer | C. O'connor | D. Mark | G. Felker | L. Cooper | K. Adams | T. Ahmad | D. Whellan | J. Januzzi | J. Ezekowitz | M. Fiuzat | Patrice Desvigne-Nickens | P. Desvigne‐Nickens | Ileana L. Piña | James L. Januzzi | Justin A. Ezekowitz | David J. Whellan | G. Michael Felker | Kirkwood F. Adams | Mona Fiuzat | Nancy Houston-Miller | Lawton S. Cooper | Eric S. Leifer | Gayle Paynter | Gayle Paynter | N. Houston-Miller | Leifer | MBBCh | Eric
[1] R. Gray,et al. A general inefficacy interim monitoring rule for randomized clinical trials , 2010, Clinical trials.
[2] V. Hasselblad,et al. Metaanalysis and review of heart failure disease management randomized controlled clinical trials. , 2005, American heart journal.
[3] K. Swedberg,et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. , 2007, JAMA.
[4] S. Réhman,et al. Characterization and prediction of natriuretic peptide "nonresponse" during heart failure management: results from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) and the NT-proBNP-Assisted Treatment to Lessen Serial Cardiac Readmissions and Death (BATTLESCARRED) study. , 2013, Congestive heart failure.
[5] J. Januzzi. The role of natriuretic peptide testing in guiding chronic heart failure management: review of available data and recommendations for use. , 2012, Archives of cardiovascular diseases.
[6] S. Yusuf,et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. , 1999, Circulation.
[7] J. Daubert,et al. Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony. , 2006, European heart journal.
[8] M. Prins,et al. Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. , 2010, Journal of the American College of Cardiology.
[9] J. Cohn,et al. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. , 2006, Clinical chemistry.
[10] W. Kraus,et al. Relationship of beta-blocker dose with outcomes in ambulatory heart failure patients with systolic dysfunction: results from the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) trial. , 2012, Journal of the American College of Cardiology.
[11] D. Moertl,et al. N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study. , 2010, Journal of the American College of Cardiology.
[12] M. Drazner,et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.
[13] K. Swedberg,et al. Improved pharmacological therapy of chronic heart failure in primary care: a randomized Study of NT‐proBNP Guided Management of Heart Failure – SIGNAL‐HF (Swedish Intervention study – Guidelines and NT‐proBNP AnaLysis in Heart Failure) , 2010, European journal of heart failure.
[14] C. Phillips,et al. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. , 2007, Journal of the American College of Cardiology.
[15] Akshay S. Desai,et al. Home Monitoring Heart Failure Care Does Not Improve Patient Outcomes: Looking Beyond Telephone-Based Disease Management , 2012, Circulation.
[16] V. Hasselblad,et al. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. , 2009, American heart journal.
[17] D. Leosco,et al. Natriuretic Peptide-Guided Therapy in Chronic Heart Failure: A Meta-Analysis of 2,686 Patients in 12 Randomized Trials , 2013, PloS one.
[18] M. Kinoshita,et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. , 2001, Journal of the American College of Cardiology.
[19] R. Califf,et al. The STARBRITE trial: a randomized, pilot study of B-type natriuretic peptide-guided therapy in patients with advanced heart failure. , 2011, Journal of cardiac failure.
[20] A. Cohen-Solal,et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. , 2007, Journal of the American College of Cardiology.
[21] C. Frampton,et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations , 2000, The Lancet.
[22] G. Fonarow,et al. Heart failure disease management programs: not a class effect. , 2004, Circulation.
[23] John G.F. Cleland,et al. Noninvasive home telemonitoring for patients with heart failure at high risk of recurrent admission and death: the Trans-European Network-Home-Care Management System (TEN-HMS) study. , 2005, Journal of the American College of Cardiology.
[24] L. Fisher,et al. Changes in Brain Natriuretic Peptide and Norepinephrine Over Time and Mortality and Morbidity in the Valsartan Heart Failure Trial (Val-HeFT) , 2003, Circulation.
[25] M. Drazner,et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.
[26] Gianni Tognoni,et al. Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). , 2008, Journal of the American College of Cardiology.
[27] J. Haybittle,et al. Repeated assessment of results in clinical trials of cancer treatment. , 1971, The British journal of radiology.
[28] Randall S Stafford,et al. The underutilization of cardiac medications of proven benefit, 1990 to 2002. , 2003, Journal of the American College of Cardiology.
[29] G. Fonarow,et al. Improving Evidence-Based Care for Heart Failure in Outpatient Cardiology Practices: Primary Results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF) , 2010, Circulation.
[30] J. Januzzi,et al. Are serial BNP measurements useful in heart failure management? Serial natriuretic peptide measurements are useful in heart failure management. , 2013, Circulation.
[31] Kevin J. Anstrom,et al. Using Inverse Probability-Weighted Estimators in Comparative Effectiveness Analyses With Observational Databases , 2007, Medical care.
[32] Peter Buser,et al. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. , 2009, JAMA.
[33] M. Zile,et al. Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study. , 2008, Journal of the American College of Cardiology.
[34] Shawn A. Gregory,et al. Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. , 2011, Journal of the American College of Cardiology.
[35] B. Billah,et al. B-type natriuretic peptide-guided heart failure therapy: A meta-analysis. , 2010, Archives of internal medicine.
[36] K. Bailey,et al. Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure. , 2005, American heart journal.
[37] C. O'connor,et al. Heart Failure Care in the Outpatient Cardiology Practice Setting: Findings From IMPROVE HF , 2008, Circulation. Heart failure.
[38] L. Tavazzi,et al. The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI‐heart failure (GISSI‐HF) trial , 2010, European journal of heart failure.
[39] C. Camargo,et al. Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. , 2006, Archives of internal medicine.
[40] M. Pike,et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.
[41] W W Hauck,et al. Should we adjust for covariates in nonlinear regression analyses of randomized trials? , 1998, Controlled clinical trials.
[42] P. Armitage,et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. , 1976, British Journal of Cancer.
[43] P. Austin,et al. Trends in heart failure outcomes and pharmacotherapy: 1992 to 2000. , 2004, The American journal of medicine.
[44] J. McMurray,et al. Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). , 2009, Journal of the American College of Cardiology.
[45] A. Hungin,et al. Barriers to accurate diagnosis and effective management of heart failure in primary care: qualitative study , 2003, BMJ : British Medical Journal.
[46] محمود فرزان. بررسی مقایسهای سطح بیومارکرN-Terminal Pro B-Type natriuretic peptide در دو روش بیهوشی عمومی و آنستزی نخاعی عملهای جراحی شکستگی شفت فمور , 2016 .